Scientific publications

External validation of the IOTA ADNEX model performed by two independent gynecologic centers

Szubert S (1), Wojtowicz A (2), Moszynski R (3), Zywica P (2), Dyczkowski K (2), Stachowiak A (2), Sajdak S (3), Szpurek D (3), Alcazar JL [SP] (4).
(1) Division of Gynecologic Surgery, Poznan University of Medical Sciences, Poland.
(2) Faculty of Mathematics and Computer Science, Adam Mickiewicz University, Poznan, Poland.
(3) Division of Gynecologic Surgery, Poznan University of Medical Sciences, Poland.
(4) Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain. 

Magazine: Gynecologic Oncology

Date: Jun 30, 2016

Gynaecology and Obstetrics

OBJECTIVES:
The external, two-center validation of the IOTA ADNEX model for differential diagnosis of adnexal tumors.

METHODS:
A total of 204 patients with adnexal masses (134 benign and 70 malignant) treated at the Division of Gynecologic Surgery, Poznan University of Medical Sciences, Poland (Center I), and 123 patients (89 benign and 34 malignant) from the Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, University of Navarra School of Medicine, Pamplona, Spain (Center II), were enrolled into the study.

RESULTS:
ADNEX achieved high accuracy in discriminating between malignant and benign ovarian tumors in both centers (79.9% and 81.3% in Centers I and II, respectively). Multiclass accuracy was substantially lower than in binary classification (malignant vs. benign): 64.2% and 74.0% in Centers I and II, respectively.

Sensitivity and specificity for the diagnosis of specific tumor types in Center I were as follows: benign tumors - 72.4% and 94.3%; borderline tumors - 33.3% and 87.0%, stage I ovarian cancers - 00.0% and 91.8%; stage II-IV ovarian cancers - 68.2% and 83.1%; and metastatic tumors - 00.0% and 99.5%. Sensitivity and specificity in Center II were as follows: benign tumors - 75.3% and 97.1%; borderline tumors - 50.0% and 88.2%, stage I ovarian cancers - 40.0% and 97.5%; stage II-IV ovarian cancers - 95.0% and 88.3%; and metastatic tumors - 20.0% and 98.3%.

CONCLUSIONS:
ADNEX is characterized by very high accuracy in differentiating between malignant and benign adnexal tumors. However, prediction of ovarian tumor types could be more accurate.

CITATION  Gynecol Oncol. 2016 Jun 30. pii: S0090-8258(16)30831-9. doi: 10.1016/j.ygyno.2016.06.020

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra